Gisadenafil

DB11902InvestigationalSmall molecule

Gisadenafil has been investigated for the treatment of Prostatic Hyperplasia.

Mechanism: Pharmacologically active on cGMP-specific 3',5'-cyclic phosphodiesterase
Curator reviewed
Formula / weight: C₂₃H₃₃N₇O₅S · 519.62 g/mol (avg)
Code names: UK-369,003

Resolves to

Compound

Structure

InChIKeyYPFZMBHKIVDSNR-UHFFFAOYSA-NSMILESCCOC1=NC=C(C=C1C1=NC2=C(CC)N(CCOC)N=C2C(=O)N1)S(=O)(=O)N1CCN(CC)CC1

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Gisadenafil, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.